Overview of early response assessment in lymphoma with FDG-PET

Por MacManus, Michael P, Seymour, John F, Hicks, Rodney J
Publicado em 2007

Negative selection of chronic lymphocytic leukaemia cells using a bifunctional rosette-based antibody cocktail

Por Essakali, Salim, Carney, Dennis, Westerman, David, Gambell, Peter, Seymour, John F, Dobrovic, Alexander
Publicado em 2008

Detection of NPM1 exon 12 mutations and FLT3 – internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia

Por Tan, Angela YC, Westerman, David A, Carney, Dennis A, Seymour, John F, Juneja, Surender, Dobrovic, Alexander
Publicado em 2008

Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features

Por Ross, David M., Bartley, Paul A., Goyne, Jarrad, Morley, Alexander A., Seymour, John F., Grigg, Andrew P.
Publicado em 2011

R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes

Por Seymour, John F., Pfreundschuh, Michael, Trnĕný, Marek, Sehn, Laurie H., Catalano, John, Csinady, Eva, Moore, Nicola, Coiffier, Bertrand
Publicado em 2014

Galectin-1 mediated suppression of Epstein-Barr virus–specific T-cell immunity in classic Hodgkin lymphoma

Por Gandhi, Maher K., Moll, Guido, Smith, Corey, Dua, Ujjwal, Lambley, Eleanore, Ramuz, Olivier, Gill, Devinder, Marlton, Paula, Seymour, John F., Khanna, Rajiv
Publicado em 2007

Epidemiology of invasive fungal disease in lymphoproliferative disorders

Por Teng, Jasmine C., Slavin, Monica A., Teh, Benjamin W., Lingaratnam, Senthil M., Ananda-Rajah, Michelle R., Worth, Leon J., Seymour, John F., Thursky, Karin A.
Publicado no Haematologica (2015)

Continued Azacitidine Therapy Beyond Time of First Response Improves Quality of Response in Patients With Higher-Risk Myelodysplastic Syndromes

Por Silverman, Lewis R., Fenaux, Pierre, Mufti, Ghulam J., Santini, Valeria, Hellström-Lindberg, Eva, Gattermann, Norbert, Sanz, Guillermo, List, Alan F., Gore, Steven D., Seymour, John F.
Publicado em 2011

Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine

Por Santini, Valeria, Fenaux, Pierre, Mufti, Ghulam J., Hellström-Lindberg, Eva, Silverman, Lewis R., List, Alan, Gore, Steven D., Seymour, John F., Backstrom, Jay, Beach, Charles L.
Publicado em 2010

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care...

Por Gore, Steven D., Fenaux, Pierre, Santini, Valeria, Bennett, John M., Silverman, Lewis R., Seymour, John F., Hellström-Lindberg, Eva, Swern, Arlene S., Beach, Charles. L., List, Alan. F.
Publicado em 2013

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

Por Komrokji, Rami S., Seymour, John F., Roberts, Andrew W., Wadleigh, Martha, To, L. Bik, Scherber, Robyn, Turba, Elyce, Dorr, Andrew, Zhu, Joy, Wang, Lixia, Granston, Tanya, Campbell, Mary S., Mesa, Ruben A.
Publicado no Blood (2015)

Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes

Por Seymour, John F., Fenaux, Pierre, Silverman, Lewis R., Mufti, Ghulam J., Hellström-Lindberg, Eva, Santini, Valeria, List, Alan F., Gore, Steven D., Backstrom, Jay, McKenzie, David, Beach, C.L.
Publicado em 2010

Phase 1 Study of the Safety, Pharmacokinetics, and Antitumour Activity of the BCL2 Inhibitor Navitoclax in Combination With Rituximab in Patients With Relapsed or Refractory CD20+...

Por Roberts, Andrew W., Advani, Ranjana H., Kahl, Brad, Persky, Daniel, Sweetenham, John W., Carney, Dennis A., Yang, Jianning, Busman, Todd B., Enschede, Sari H., Humerickhouse, Roderick A., Seymour, John F.
Publicado no Br J Haematol (2015)

Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan

Por Ishii, Haruyuki, Seymour, John F, Tazawa, Ryushi, Inoue, Yoshikazu, Uchida, Naoyuki, Nishida, Aya, Kogure, Yoshihito, Saraya, Takeshi, Tomii, Keisuke, Takada, Toshinori, Itoh, Yuko, Hojo, Masayuki, Ichiwata, Toshio, Goto, Hajime, Nakata, Koh
Publicado em 2014

5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimerse...

Por O'Brien, Susan, Moore, Joseph O., Boyd, Thomas E., Larratt, Loree M., Skotnicki, Aleksander B., Koziner, Benjamin, Chanan-Khan, Asher A., Seymour, John F., Gribben, John, Itri, Loretta M., Rai, Kanti R.
Publicado no J Clin Oncol (2009)

Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C

Por Fenaux, Pierre, Gattermann, Norbert, Seymour, John F., Hellström-Lindberg, Eva, Mufti, Ghulam J., Duehrsen, Ulrich, Gore, Steven D., Ramos, Fernando, Beyne-Rauzy, Odile, List, Alan, McKenzie, David, Backstrom, Jay, Beach, Charles L.
Publicado em 2010

The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lym...

Por Rule, Simon, Smith, Paul, Johnson, Peter W.M., Bolam, Simon, Follows, George, Gambell, Joanne, Hillmen, Peter, Jack, Andrew, Johnson, Stephen, Kirkwood, Amy A, Kruger, Anton, Pocock, Christopher, Seymour, John F., Toncheva, Milena, Walewski, Jan, Linch, David
Publicado no Haematologica (2016)

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

Por Anderson, Mary Ann, Deng, Jing, Seymour, John F., Tam, Constantine, Kim, Su Young, Fein, Joshua, Yu, Lijian, Brown, Jennifer R., Westerman, David, Si, Eric G., Majewski, Ian J., Segal, David, Heitner Enschede, Sari L., Huang, David C. S., Davids, Matthew S., Letai, Anthony, Roberts, Andrew W.
Publicado no Blood (2016)

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-depe...

Por Cappellini, Maria Domenica, Porter, John, El-Beshlawy, Amal, Li, Chi-Kong, Seymour, John F., Elalfy, Mohsen, Gattermann, Norbert, Giraudier, Stéphane, Lee, Jong-Wook, Chan, Lee Lee, Lin, Kai-Hsin, Rose, Christian, Taher, Ali, Thein, Swee Lay, Viprakasit, Vip, Habr, Dany, Domokos, Gabor, Roubert, Bernard, Kattamis, Antonis
Publicado em 2010

Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib

Por Cheah, Chan Y., Burbury, Kate, Apperley, Jane F., Huguet, Francoise, Pitini, Vincenzo, Gardembas, Martine, Ross, David M., Forrest, Donna, Genet, Philippe, Rousselot, Philippe, Patton, Nigel, Smith, Graeme, Dunbar, Cynthia E., Ito, Sawa, Aguiar, Ricardo C. T., Odenike, Olatoyosi, Gimelfarb, Alla, Cross, Nicholas C. P., Seymour, John F.
Publicado em 2014